These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38268743)

  • 1. The comparability tales: A phase-appropriate roadmap for CGT drug product development.
    ; Clément N; Kassim SH; Leblanc D; Spink K; Tomtishen J
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101170. PubMed ID: 38268743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.
    Schrieber SJ; Putnam WS; Chow ECY; Cieslak J; Zhuang Y; Martin SW; Hanson P; Maggio F; Rosado LAR
    Drugs R D; 2020 Dec; 20(4):301-306. PubMed ID: 32914381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
    Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
    Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
    Zhuang Y; Chen D; Sharma A; Xu Z
    AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products.
    Kendrick BS; Gabrielson JP; Hunt D; Christie M; Bowen S; Vessely C; Rogers RS; Cleveland C; Maluf K; Roach S; Ritter N
    J Pharm Sci; 2024 Nov; 113(11):3123-3136. PubMed ID: 39313151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
    Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
    AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspective.
    El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Newman B; Spagnola M; Walenga RL; Zhao L
    Adv Drug Deliv Rev; 2022 Oct; 189():114519. PubMed ID: 36038083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality control system to support comparability assessment for the Renal Bio-Replacement therapy system.
    Pitkin Z
    Dev Biol (Basel); 2005; 122():131-8. PubMed ID: 16375257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations.
    Salazar-Fontana LI
    Front Med (Lausanne); 2022; 9():855100. PubMed ID: 35646952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate data analysis in cell gene therapy manufacturing.
    Emerson J; Kara B; Glassey J
    Biotechnol Adv; 2020 Dec; 45():107637. PubMed ID: 32980438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment.
    Li Z; Du X; Wang YC
    Pharm Res; 2024 Jan; 41(1):13-27. PubMed ID: 37910341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-centric Comparability Assessment of Biopharmaceuticals.
    Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
    J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scaling of cell and gene therapies to population.
    Knöbel S; Bosio A
    Handb Clin Neurol; 2024; 205():145-154. PubMed ID: 39341651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).
    Harrison RP; Chauhan VM
    Biointerphases; 2017 Dec; 13(1):01A301. PubMed ID: 29246035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.
    Scott M; Clarke D; Lipsitz Y; Brandwein H; Allickson J; Alzebdeh D; Aleksic S; Kraft C; Lhu L; Cornetta K
    Cytotherapy; 2020 Nov; 22(11):669-676. PubMed ID: 32713719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
    Hourd P; Ginty P; Chandra A; Williams DJ
    Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.